Targeting claudins in cancer: diagnosis, prognosis and therapy

xlomafota13 shared this article with you from Inoreader Targeting claudins in cancer: diagnosis, prognosis and therapy Via American Journal of Cancer Research Am J Cancer Res. 2021 Jul 15;11(7):3406-3424. eCollection 2021. ABSTRACT Increasing evidence has linked claudins to signal transduction and tumorigenesis. The expression of claudins is frequently dysregulated in the context of neoplastic transformation, suggesting their promise as biomarkers for diagnosis and prognosis or targets for treatment. Claudin binders (Clostridium perfringens enterotoxin and monoclonal antibody) have been tested in preclinical experiments, and some of them have progressed into clinical trials involving patients with certain cancers. However, the clinical development of many of these agents has not advanced to clinical applications. Herein, I review the current status of preclinical and clinical investigations of agents targeting claudins for diagnosis, prognosis and therapy. I also discuss the potential of combining claudin binders with other currently approved therapeutic agents. PMID:34354852 | PMC:PMC8332862 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.